SCHEMBL7185192

SCHEMBL7185192

COc1cccc(Cl)c1C(=O)P(=O)(C(=O)c1ccccc1)c1c(C)cccc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.41
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.40
KMT2A Q03164 1/20 0.40
CHRNA7 P36544 1/20 0.38
ATM Q13315 1/20 0.38
FFAR2 O15552 6/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
KDM4E B2RXH2 2/20 0.37
HTT P42858 2/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
KAT6A Q92794 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
TUBB4A P04350 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7190527 0.92 ATM (0.41) ALDH1A1LMNAKMT2AATMFFAR2
SCHEMBL7177270 0.90 ATM (0.41) FABP4ALDH1A1KMT2AATMCA12
SCHEMBL7184560 0.90 ITGB1 (0.39) FABP4ALDH1A1LMNAKMT2AL3MBTL1
SCHEMBL7175131 0.89 ITGB1 (0.40) FABP4ALDH1A1LMNAKMT2AL3MBTL1
SCHEMBL7182181 0.87 ATM (0.42) FABP4ALDH1A1KMT2AATMCA12
SCHEMBL7189406 0.84 HTT (0.42) ALDH1A1LMNAKMT2AL3MBTL1KDM4E
SCHEMBL7175566 0.83 TRPM4 (0.41) FABP4ALDH1A1ATMCA12CA1
SCHEMBL7180582 0.83 NR1H4 (0.40) ALDH1A1KMT2AL3MBTL1KDM4EHTT
SCHEMBL7180075 0.83 FABP4 (0.38) FABP4ALDH1A1KMT2AATMCA12
SCHEMBL7185193 0.83 CHRNA7 (0.43) FABP4ALDH1A1LMNAKMT2ACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 FABP4 4550/4885ALDH1A1 3416/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 FABP4 4256/4885ALDH1A1 3984/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.